Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Recruiting
Observational Study
Non-small Cell Lung Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 800 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
* Uncommon EGFR Mutant Advanced NSCLC
Exclusion Criteria:
* Patients with contraindication of chemotherapy
* Pregnant or breast feeding women
Contacts